Oncogenex Pharmaceuticals In
|
Q3 2017
Filed on Aug 30, 2024
|
9,000
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
1,000
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
585,039
|
N/A
|
|
Peregrine Pharmaceuticals In
|
Q3 2017
Filed on Aug 30, 2024
|
1,140
|
N/A
|
|
|
Q3 2017
Filed on Aug 30, 2024
|
205
|
N/A
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
130
|
$23.74 - $31.22
$3.09K - $4.06K
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
59,238
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
60
|
N/A
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
1,000
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
12
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
1,000
|
$6.47 - $11.46
$6.47K - $11.5K
|
|
|
Q3 2018
Filed on Aug 30, 2024
|
2,500
|
N/A
|
|
|
Q3 2018
Filed on Aug 30, 2024
|
26,030
|
$15.76 - $21.04
$410K - $548K
|
|
|
Q3 2018
Filed on Aug 30, 2024
|
13,889
|
N/A
|
|
Capital Product Partners L P
|
Q4 2017
Filed on Aug 30, 2024
|
31,174
|
N/A
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
61,793
|
N/A
|
|
Enel Generacion Chile S A
|
Q3 2017
Filed on Aug 30, 2024
|
945
|
N/A
|
|
|
Q3 2017
Filed on Aug 30, 2024
|
6,221
|
N/A
|
|
|
Q3 2017
Filed on Aug 30, 2024
|
350,000
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
13,226
|
$12.52 - $17.82
$166K - $236K
|
|
|
Q3 2017
Filed on Aug 30, 2024
|
4,080
|
$12.09 - $13.03
$49.3K - $53.2K
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
1,112
|
$32.65 - $37.9
$36.3K - $42.1K
|
|
|
Q3 2017
Filed on Aug 30, 2024
|
14,119
|
N/A
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
11,392
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
4,010
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
818
|
N/A
|
|
|
Q3 2018
Filed on Aug 30, 2024
|
3,000
|
$2.24 - $3.11
$6.72K - $9.33K
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
11
|
N/A
|
|
Arena Pharmaceuticals Inc
|
Q4 2017
Filed on Aug 30, 2024
|
25
|
N/A
|
|
|
Q3 2018
Filed on Aug 30, 2024
|
400
|
N/A
|
|
Blue Buffalo Pet Prods Inc
|
Q1 2018
Filed on Aug 30, 2024
|
80
|
N/A
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
500
|
$15.38 - $23.91
$7.69K - $12K
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
150
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
500
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
290
|
$106.2 - $124.55
$30.8K - $36.1K
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
500
|
$1.55 - $2.3
$775 - $1.15K
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
3,660
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
1,400
|
N/A
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
1,000
|
$22.34 - $25.79
$22.3K - $25.8K
|
|
|
Q2 2018
Filed on Aug 30, 2024
|
1,250
|
$16.3 - $18.18
$20.4K - $22.7K
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
460
|
$34.38 - $40.23
$15.8K - $18.5K
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
6,000
|
$3.89 - $4.17
$23.3K - $25K
|
|
Peregrine Pharmaceuticals In
|
Q1 2018
Filed on Aug 30, 2024
|
162
|
N/A
|
|
|
Q1 2018
Filed on Aug 30, 2024
|
2,000
|
$11.12 - $11.98
$22.2K - $24K
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
2,500
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
51,300
|
N/A
|
|
Powershares Global ETF Fd
|
Q2 2018
Filed on Aug 30, 2024
|
11,340
|
N/A
|
|
|
Q3 2018
Filed on Aug 30, 2024
|
20
|
N/A
|
|
|
Q4 2017
Filed on Aug 30, 2024
|
818,118
|
N/A
|
|
Social Cap Hedosophia Hldgs
|
Q1 2018
Filed on Aug 30, 2024
|
5,000
|
N/A
|
|